NK Cell Lectin-Like Receptor Subfamily K
"NK Cell Lectin-Like Receptor Subfamily K" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An activating NK cell lectin-like receptor subfamily that regulates immune responses to INFECTION and NEOPLASMS. Members of this subfamily generally occur as homodimers.
| Descriptor ID |
D055655
|
| MeSH Number(s) |
D12.776.543.750.705.895.800.910
|
| Concept/Terms |
NK Cell Lectin-Like Receptor Subfamily K- NK Cell Lectin-Like Receptor Subfamily K
- NK Cell Lectin Like Receptor Subfamily K
- Killer Cell Lectin-Like Receptor Subfamily K
- Killer Cell Lectin Like Receptor Subfamily K
NK Cell Lectin-Like Receptor Subfamily K, Member 1- NK Cell Lectin-Like Receptor Subfamily K, Member 1
- NK Cell Lectin Like Receptor Subfamily K, Member 1
- NKG2D Receptor
- Receptor, NKG2D
- CD314 Antigen
- Antigen, CD314
- NKG2-D Receptor
- NKG2 D Receptor
- Receptor, NKG2-D
- Killer Cell Lectin-Like Receptor Subfamily K, Member 1
- Killer Cell Lectin Like Receptor Subfamily K, Member 1
- NK Cell Receptor D
|
Below are MeSH descriptors whose meaning is more general than "NK Cell Lectin-Like Receptor Subfamily K".
Below are MeSH descriptors whose meaning is more specific than "NK Cell Lectin-Like Receptor Subfamily K".
This graph shows the total number of publications written about "NK Cell Lectin-Like Receptor Subfamily K" by people in this website by year, and whether "NK Cell Lectin-Like Receptor Subfamily K" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "NK Cell Lectin-Like Receptor Subfamily K" by people in Profiles.
-
NKG2D blockade impairs tissue-resident memory T cell accumulation and reduces chronic lung allograft dysfunction. JCI Insight. 2025 Feb 24; 10(4).
-
Tissue-resident natural killer cells support survival in pancreatic cancer through promotion of cDC1-CD8 T activity. Elife. 2024 Dec 10; 13.
-
NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. Cancer Immunol Res. 2024 Oct 01; 12(10):1421-1437.
-
Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-ß-activated kinase 1. Oncoimmunology. 2022; 11(1):2016159.
-
Tumor-derived NKG2D ligand sMIC reprograms NK cells to an inflammatory phenotype through CBM signalosome activation. Commun Biol. 2021 07 22; 4(1):905.
-
Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy. 2020 08; 22(8):450-457.
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020 06 09; 13(1):74.
-
Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. J Immunother Cancer. 2019 08 26; 7(1):223.
-
NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. AIDS Res Hum Retroviruses. 2016 Oct/Nov; 32(10-11):1089-1096.
-
Cysteinyl leukotrienes mediate lymphokine killer activity induced by NKG2D and IL-15 in cytotoxic T cells during celiac disease. J Exp Med. 2015 Sep 21; 212(10):1487-95.